{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:12:39Z","timestamp":1778271159775,"version":"3.51.4"},"reference-count":21,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The mucosal-associated lymphoid tissue (MALT)\u2013International Prognostic Index (IPI) is widely applied to estimate outcomes in patients with extranodal marginal zone lymphoma (EMZL) of MALT. Although it was developed in the context of the IELSG-19 trial exclusively in patients treated with chlorambucil, rituximab, or their combination, it is commonly used across virtually all disease settings. However, its applicability beyond contexts resembling the IELSG-19 trial remains debated, and several studies have proposed modifications to improve prognostic precision in EMZL. Here, we retrospectively analyzed 498 patients with newly diagnosed EMZL at the Medical University of Vienna with the dual objective of evaluating the prognostic performance of the MALT-IPI across clinical subgroups, and to assess whether incorporation of autoimmunity could refine risk stratification. Stratification by the MALT-IPI revealed significantly longer progression-free survival (PFS) and overall survival (OS) in patients who were low-risk compared with intermediate- and high-risk groups (P&amp;lt; .001) in unselected patients. However, in subgroup analyses, its discriminatory capacity was restricted to patients with extragastric disease, particularly patients with EMZL of the ocular adnexa or the parotid gland or intestinal EMZL, as well as those receiving systemic therapy. On the contrary, patients with gastric EMZL or those managed with Helicobacter pylori eradication, local therapy, or watch-and-wait approaches did not derive consistent prognostic separation. Incorporation of autoimmunity identified a small subgroup with inferior PFS and OS, but provided limited incremental prognostic power beyond the established index in most patients. Our results support context-specific applicability of the MALT-IPI, and highlight autoimmunity as a prognostically relevant factor in a small cohort of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019076","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T19:53:41Z","timestamp":1772567621000},"page":"3186-3197","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Field-testing the MALT-IPI in a single-center real-world cohort of patients with extranodal marginal zone lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9151-4139","authenticated-orcid":false,"given":"Vincent","family":"Sunder-Plassmann","sequence":"first","affiliation":[{"name":"1Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"},{"name":"2Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5490-2371","authenticated-orcid":false,"given":"Barbara","family":"Kiesewetter","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3814-7492","authenticated-orcid":false,"given":"Ingrid","family":"Simonitsch-Klupp","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Brand","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7450-4215","authenticated-orcid":false,"given":"Werner","family":"Dolak","sequence":"additional","affiliation":[{"name":"4Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8786-8686","authenticated-orcid":false,"given":"Marius E.","family":"Mayerhoefer","sequence":"additional","affiliation":[{"name":"5Division of Oncologic Imaging, Department of Radiology, NYU Langone Health, NYU Grossman School of Medicine, New York, NY"},{"name":"6Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-5802","authenticated-orcid":false,"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"7","key":"2026050815180926900_bib1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"2026050815180926900_bib2","first-page":"153","article-title":"Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","volume":"66","author":"Raderer","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2026050815180926900_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"key":"2026050815180926900_bib4","doi-asserted-by":"crossref","first-page":"17588359211033825","DOI":"10.1177\/17588359211033825","article-title":"What you always wanted to know about gastric MALT-lymphoma: a focus on recent developments","volume":"13","author":"Raderer","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"2026050815180926900_bib5","doi-asserted-by":"crossref","first-page":"e000812","DOI":"10.1136\/esmoopen-2020-000812","article-title":"How I treat MALT lymphoma: \u2018a subjective interpretation of the gospel according to Isaacson\u2026\u2019","volume":"5","author":"Raderer","year":"2020","journal-title":"ESMO Open"},{"issue":"3","key":"2026050815180926900_bib6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"issue":"suppl 6","key":"2026050815180926900_bib7","doi-asserted-by":"crossref","first-page":"vi144","DOI":"10.1093\/annonc\/mdt343","article-title":"Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Zucca","year":"2013","journal-title":"Ann Oncol"},{"issue":"11","key":"2026050815180926900_bib8","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3324\/haematol.2019.237990","article-title":"Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment","volume":"105","author":"Annarita","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"2026050815180926900_bib9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ajh.25473","article-title":"The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas","volume":"94","author":"Tracy","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"2026050815180926900_bib10","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2026050815180926900_bib11","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026050815180926900_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00277-018-3516-1","article-title":"Validation of the marginal zone lymphoma International Prognostic Index","volume":"98","author":"Hong","year":"2019","journal-title":"Ann Hematol"},{"issue":"12","key":"2026050815180926900_bib13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/ajh.26715","article-title":"Revised MALT-IPI: a new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma","volume":"97","author":"Alderuccio","year":"2022","journal-title":"Am J Hematol"},{"issue":"8","key":"2026050815180926900_bib14","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/cancers13081803","article-title":"Treatments and outcomes in stage I extranodal marginal zone lymphoma in the United States","volume":"13","author":"Alderuccio","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"2026050815180926900_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-018-0105-4","article-title":"History of autoimmune conditions and lymphoma prognosis","volume":"8","author":"Kleinstern","year":"2018","journal-title":"Blood Cancer J"},{"issue":"8","key":"2026050815180926900_bib16","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/sj.leu.2404782","article-title":"MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course","volume":"21","author":"W\u00f6hrer","year":"2007","journal-title":"Leukemia"},{"issue":"7","key":"2026050815180926900_bib17","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1023\/A:1011122904602","article-title":"Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease","volume":"12","author":"Raderer","year":"2001","journal-title":"Ann Oncol"},{"issue":"4","key":"2026050815180926900_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF00573019","article-title":"Prognosis of non-Hodgkin's lymphomas with special emphasis on the staging classification","volume":"83","author":"Musshoff","year":"1975","journal-title":"Z Krebsforsch Klin Onkol Cancer Res Clin Oncol"},{"issue":"4","key":"2026050815180926900_bib19","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00277-023-05130-8","article-title":"Long-term clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma in real-world experience","volume":"102","author":"Min","year":"2023","journal-title":"Ann Hematol"},{"issue":"3","key":"2026050815180926900_bib20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3748\/wjg.v20.i3.684","article-title":"Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas","volume":"20","author":"Pereira","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"10","key":"2026050815180926900_bib21","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/ajh.27058","article-title":"Marginal zone lymphoma: 2023 update on diagnosis and management","volume":"98","author":"Cheah","year":"2023","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3186\/2516462\/blooda_adv-2025-019076-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3186\/2516462\/blooda_adv-2025-019076-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:18:13Z","timestamp":1778267893000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3186\/566914\/Field-testing-the-MALT-IPI-in-a-single-center-real"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019076","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,5,1]]}}}